Viralgen
San Sebastián, Spain viralgen.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
Viralgen is an AAV-based gene therapy CDMO that provides end-to-end manufacturing support from construct optimization and plasmid DNA production through clinical and commercial production. It serves biotech and pharmaceutical clients developing gene therapies for rare, ultra-rare, and other genetic diseases from its facilities in San Sebastián, Spain.
Services
Process development
Supports early-stage programs with platform fit, construct optimization, and production strategy, and supports late-stage programs with comparability studies, next-generation process transition, and process characterization/PPQ.
AAV manufacturing platform
Uses the Aava™ platform and Pro10™ cell line to manufacture AAV gene therapies with a high-yield, scalable process.
Early phase production
Produces material for development, toxicology, and Phase I clinical needs from small screening batches through cGMP batches.
Late phase production
Provides manufacturing support for late-stage clinical development and commercialization, including process characterization and PPQ planning.
Commercial production
Provides large-scale AAV manufacturing for commercial supply, including scale-up and scale-out to meet demand.
Fill and finish
Performs fill and finish in dedicated suites with automated isolator-based operations.
QC release
Carries out quality control release work, with much of the QC and CMC work performed in-house.
MSAT services
Supports manufacturing science and technology activities, including process characterization and scale-down studies.
1 more services
- Plasmid DNA production
Capabilities
- Assays and studies
- AAV
- Process development
- Bioreactors
- HEK293
- Toxicology
- Fill-finish
5 more
- ELISA
- DNA analysis
- Physicochemical testing
- Analytical characterization
- Process characterization
- Scale and capacity
- 2L screening batches
- 50L toxicology batches
- 250L-500L cGMP batches
- Up to 1,500L per batch
- Up to 2,000L single-use bioreactors per suite
- 3 modules
5 more
- Up to 3 production trains per module
- 343,000+ square feet
- 45,000 square feet of clinical-stage infrastructure
- 300,000+ square feet of commercial readiness
- 1000m2 MSAT cGMP-like laboratory
- Therapeutic areas
- Gene therapy
- Rare diseases
- Ultra-rare diseases
- Pathway diseases
- Drug-resistant focal epilepsy
- Spastic Paraplegia 50
6 more
- Charcot-Marie-Tooth disease type 4J
- AADC deficiency
- NPC
- NPA
- Duchenne muscular dystrophy exon 1 deletion
- MPS IIIC
Instruments and platforms
- Ambr250 HT system
- Ultracentrifugation
- Depth filtration
- Chromatography skids
- Tangential flow filtration
Modalities and species
- Modalities
- Viral vector
- Cell therapy
- Plasmid DNA
- Species and models
- HEK293-derived cell line
- Pro10™ suspension cell line
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances
Details
- Type
- CDMO
- Founded
- 2017
- Team
- 400+ professionals
- Based in
- San Sebastián, Spain
- Sites
- San Sebastián, Spain